Premium
Markers of joint tissue turnover in joint fluids from hips with osteonecrosis of the femoral head
Author(s) -
Jingushi Seiya,
Lohmander L. Stefan,
Shinmei Masayuki,
Hoerrner Lori A.,
Lark Michael W.,
Sugioka Yoichi,
Iwamoto Yukihide
Publication year - 2000
Publication title -
journal of orthopaedic research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.041
H-Index - 155
eISSN - 1554-527X
pISSN - 0736-0266
DOI - 10.1002/jor.1100180508
Subject(s) - femoral head , osteoarthritis , medicine , cartilage , stage (stratigraphy) , aggrecan , synovial fluid , cartilage oligomeric matrix protein , arthropathy , pathology , articular cartilage , surgery , anatomy , biology , paleontology , alternative medicine
Osteonecrosis of the femoral head often results in secondary osteoarthritis of the hip joint; however, the pathologic processes underlying the destruction of articular cartilage are not fully understood. Molecular markers in the hip joint fluids were measured to examine the changes in turnover of cartilage and other joint tissues. Marker data were related to clinical, radiological, and histopathological changes in the articular cartilage of the hip. Forty‐five patients (median age: 43 years) were studied. The median time between the onset of symptoms and sampling of hip synovial fluid was 6 months. Aggrecan fragments, C‐propeptide of type‐II collagen, matrix metalloproteinase‐3, and tissue inhibitor of metalloproteinases‐1 levels in joint fluid were determined by immunoassay. Osteonecrosis of the femoral head was graded by radiology as minimal collapse of the femoral head (stage 2: 26 patients), severe collapse (stage 3: 15 patients), or severe collapse with osteoarthritis (stage 4: four patients). Histologica changes of the articular cartilage, consistent with early‐stage osteoarthritis, were evident at stage 3 and were more advanced at stage 4. The average concentrations of proteoglycan fragments and C‐propeptide of type‐II collagen were 207 (SD 182) μg/ml and 19.6 (SD 19.3) ng/ml, respectively. The average concentrations of matrix metalloproteinase‐3 and tissue inhibitor of metalloproteinases‐ 1 were 177 (SD 291) nM and 23.0 (SD 9.9) n M , respectively. Measurable levels for all markers assayed were noted in the earliest stage of the disease, only a few months after the onset of symptoms and well before the appearance of radiological changes. Levels of matrix metalloproteinase‐3 and molar ratios of matrix metalloproteinase‐3/tissue inhibitor of metalloproteinases‐1 were higher in early stage disease than in later stage disease.